CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. (CERO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cero · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CERo Therapeutics Holdings, Inc. (CERO) measures how much investors pay for each dollar of the company's trailing earnings. CERO's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.72.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2021 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CERo Therapeutics Holdings, Inc.You CERO | $0M | N/A | — | -$0.72 |
 BriaCell Therapeutics Corp. Warrant BCTXZ | $0M | N/A | — | -$62.95 |
 BioVie Inc. BIVI | $13M | N/A | — | -$11.87 |
 PMGC Holdings Inc. ELAB | $3M | N/A | — | -$378.74 |
 Galmed Pharmaceuticals Ltd. GLMD | $3M | N/A | — | -$2.39 |
 Liminatus Pharma, Inc. Class A Common Stock LIMN | $4M | N/A | — | -$0.43 |
 Moolec Science S.A. MLEC | $5M | N/A | — | -$258.69 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-4.71 | — | |
2024-12-31 FY2024 | — | $-64.01 | — | |
2023-12-31 FY2023 | — | $-0.34 | — | |
2022-12-31 FY2022 | — | $-90.81 | — | |
2021-12-31 FY2021 | — | $-42.91 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CERo Therapeutics Holdings, Inc. (CERO) measures how much investors pay for each dollar of the company's trailing earnings. CERO's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.72.
Frequently asked questions
CERO pe ratio · 6 questionsCERO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.01 and TTM EPS of -$0.72. Data sourced from Financial Modeling Prep via CERO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CERo Therapeutics Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09